Cognition Therapeutics Reports Positive Phase 2 Study Results for CT1812 in Dementia with Lewy Bodies

December 18, 2024

DENVER, Colo., Dec 18, 2024 (247marketnews.com)- Cognition Therapeutics (NASDAQ: CGTX) reported positive topline results from the exploratory Phase 2 ‘SHIMMER’ study demonstrating that CT1812 produced strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with dementia with Lewy bodies (DLB).

James E. Galvin, MD, MPH, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and a principal investigator in the SHIMMER study, stated, “The results from this exploratory Phase 2 trial demonstrated CT1812 could have a meaningful, positive impact on DLB patients across multiple measures of cognitive, behavioral, movement, and functional performance. DLB is a multifactorial disease where patients experience a constellation of symptoms, and the results of this study suggest CT1812 holds promise for DLB patients and their care providers. I believe the SHIMMER topline results are both exciting and very promising, and I am looking forward to working with the team at Cognition as they determine the appropriate next steps for CT1812.”

The SHIMMER Phase 2 study results indicate the primary endpoint of safety and tolerability were met.

There was an 82% slowing in the total neuropsychiatric inventory (NPI) with a particularly strong reduction in anxiety, hallucinations, and delusions in the CT1812 treated arms and a marked reduction in caregiver distress.

Anthony Caggiano, M.D., Ph.D., Cognition’s chief medical officer and head of R&D, commented, “These topline results exceeded our expectations and support the broad potential of CT1812 across neurodegenerative disorders. Analysis of CT1812’s activity in DLB will continue as additional data become available. We look forward to reporting these findings at future medical meetings and reviewing them with the FDA in an end-of-Phase 2 meeting.”

Lisa Ricciardi, Cognition’s president and CEO, added, “With the SHIMMER and SHINE results, we are confident in CT1812’s clinical activity given that it has demonstrated broad neurologic and neuroprotective activity in DLB and Alzheimer’s disease. People with these diseases, particularly DLB, have few therapeutic options leading to a cascade of symptoms that are painful to the individual and their caregivers. We are eager to continue the development of CT1812 in late-stage clinical trials with the hope of providing a once-daily pill that can treat these devasting neurodegenerative conditions.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (CGTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.